High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients

References

• Akrida I, Bravou V, Papadaki H. 2022. The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer. Mol Biol Rep. 49(10):10065–10076. doi:10.1007/s11033-022-07590-z
   PubMed Web of Science ®Google Scholar
• Angus L, Moleirinho S, Herron L, Sinha A, Zhang X, Niestrata M, Dholakia K, Prystowsky MB, Harvey KF, Reynolds PA, et al. 2012. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene. 31(2):238–250. doi: 10.1038/onc.2011.224
   PubMed Web of Science ®Google Scholar
• Babaei G, Aziz SG, Jaghi NZZ. 2021. EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed Pharmacother. 133:110909. doi:10.1016/j.biopha.2020.110909
   PubMed Web of Science ®Google Scholar
• Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. 2018. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 11(4):264–273. doi: 10.14740/gr1062w
   PubMed Web of Science ®Google Scholar
• Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, 3rd, et al. 2004. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 22(16):3408–3419. doi:10.1200/JCO.2004.05.063
   PubMed Web of Science ®Google Scholar
• Bufill JA. 1990. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 113(10):779–788. doi:10.7326/0003-4819-113-10-779
   PubMed Web of Science ®Google Scholar
• De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, et al. 2013. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 19(5):614–618. Human Protein Atlas, proteinatlas.org. doi:10.1038/nm.3174
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. 2015. The consensus molecular subtypes of colorectal cancer. Nat Med. 21(11):1350–1356. doi:10.1038/nm.3967
   PubMed Web of Science ®Google Scholar
• Haldrup J, Strand SH, Cieza-Borrella C, Jakobsson ME, Riedel M, Norgaard M, Hedensted S, Dagnaes-Hansen F, Ulhoi BP, Eeles R, et al. 2021. FRMD6 has tumor suppressor functions in prostate cancer. Oncogene. 40(4):763–776. doi:10.1038/s41388-020-01548-w
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. 2013. The Hippo pathway and human cancer. Nat Rev Cancer. 13(4):246–257. doi:10.1038/nrc3458
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. 2013. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi64–72. doi:10.1093/annonc/mdt354
   PubMed Web of Science ®Google Scholar
• Li Y, Yao Q, Zhang L, Mo S, Cai S, Huang D, Peng J. 2020. Immunohistochemistry-based consensus molecular subtypes as a prognostic and predictive biomarker for adjuvant chemotherapy in patients with stage II colorectal cancer. Oncologist. 25(12):e1968–e1979. doi:10.1002/ONCO.13521
   PubMed Web of Science ®Google Scholar
• Ling H-H, Kuo C-C, Lin B-X, Huang Y-H, Lin C-W. 2017. Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. Exp Cell Res. 350(1):218–225. doi: 10.1016/j.yexcr.2016.11.024
   PubMed Web of Science ®Google Scholar
• Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F, et al. 2022. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 72(2):338–344. doi:10.1136/gutjnl-2022-327736
   PubMed Web of Science ®Google Scholar
• Nozawa H, Kawai K, Hata K, Tanaka T, Nishikawa T, Otani K, Sasaki K, Kaneko M, Emoto S, Murono K, et al. 2018. High-risk Stage II colorectal cancers carry an equivalent risk of peritoneal recurrence to stage III. In Vivo. 32(5):1235–1240. doi:10.21873/invivo.11370
   PubMed Web of Science ®Google Scholar
• Pan D. 2010. The hippo signaling pathway in development and cancer. Dev Cell. 19(4):491–505. doi:10.1016/j.devcel.2010.09.011
   PubMed Web of Science ®Google Scholar
• Saitoh M. 2018. Involvement of partial EMT in cancer progression. J Biochem. 164(4):257–264. doi:10.1093/jb/mvy047
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al. 2012. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 23(10):2479–2516. doi:10.1093/annonc/mds236
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Wang J, Li Z, Wang X, Ding Y, Li N. 2020. The tumor suppressive effect of long non-coding RNA FRMD6-AS2 in uteri corpus endometrial carcinoma. Life Sci. 243:117254. doi:10.1016/j.lfs.2020.117254
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao C, Quan F, Zhang P, Shao Y, Liu L. 2022. FERM domain-containing protein 6 exerts a tumor-inhibiting role in thyroid cancer by antagonizing oncogenic YAP1. Biofactors. 48(2):428–441. doi:10.1002/biof.1791
   PubMed Web of Science ®Google Scholar
• Wierzbicki PM, Rybarczyk A. 2015. The Hippo pathway in colorectal cancer. Folia Histochem Cytobiol. 53(2):105–119. doi:10.5603/FHC.a2015.0015
   PubMed Web of Science ®Google Scholar